KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $3.5 million.

  • GoodRx Holdings' Change in Account Payables rose 16871.84% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year increase of 18183.03%. This contributed to the annual value of -$21.2 million for FY2024, which is 22168.31% down from last year.
  • Latest data reveals that GoodRx Holdings reported Change in Account Payables of $3.5 million as of Q3 2025, which was up 16871.84% from $10.8 million recorded in Q2 2025.
  • Over the past 5 years, GoodRx Holdings' Change in Account Payables peaked at $25.5 million during Q3 2023, and registered a low of -$15.6 million during Q2 2024.
  • Over the past 5 years, GoodRx Holdings' median Change in Account Payables value was -$26000.0 (recorded in 2021), while the average stood at $745947.4.
  • Within the past 5 years, the most significant YoY rise in GoodRx Holdings' Change in Account Payables was 1003076.92% (2022), while the steepest drop was 93378.15% (2022).
  • Quarter analysis of 5 years shows GoodRx Holdings' Change in Account Payables stood at -$115000.0 in 2021, then soared by 6306.09% to $7.1 million in 2022, then plummeted by 58.79% to $2.9 million in 2023, then tumbled by 34.51% to $1.9 million in 2024, then skyrocketed by 83.75% to $3.5 million in 2025.
  • Its Change in Account Payables stands at $3.5 million for Q3 2025, versus $10.8 million for Q2 2025 and $286000.0 for Q1 2025.